Search
Gibco CTS AIM V SFM（治療グレード）は、T細胞および樹状細胞の増殖や操作のための初めの商用無血清培地（SFM）であり、cGMPに準拠して製造されています。これにはL-グルタミン、50µg/mLのストレプトマイシン硫酸塩、および10µg/mLのゲンタマイシン硫酸塩が含まれています。
細胞ベース、遺伝子ベース、または組織ベースの製品の研究での用途または製造。注意：ヒトまたは動物への直接投与は意図されていません。
仕様
細胞タイプMonocytes, Dendritic Cells, T Cells, Hybridomas, PBMCs, Fibroblasts, Macrophages, Myeloma Cells, Lymphocytes
使用対象（アプリケーション）Cell and Gene Therapy Research, Development, and Manufacturing
フォーマットBottle
製造品質ISO 13485, MDSAP, FDA-registered, 21 CFR 820
製品タイプCell Culture Medium
数量1 L
品質保持期間14 months from date of manufacture
出荷条件Ambient
分類Animal Origin
形状Liquid
Serum LevelSerum-free
無菌性Sterile-filtered
Unit SizeEach
組成および保存条件
Store at 2–8°C and protect from light.
よくあるご質問（FAQ）
What is CTS?
What is the difference between AIM V Medium (Cat. Nos. 12055083, 12055091) and CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK)?
What is the difference between CTS AIM-V Medium and CTS AIM V SFM?
引用および参考文献 (31)
引用および参考文献
Abstract
Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.
Journal:J Immunol
PubMed ID:17878372
'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause
[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]
Journal:Nippon Hinyokika Gakkai Zasshi
PubMed ID:8320888
'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.
Journal:J Immunol Methods
PubMed ID:18242633
'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the
CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells.
Journal:Eur J Immunol
PubMed ID:14971034
We studied the contribution of CD4 T cell help to survival and competitive fitness of CD8 memory T cells specific for influenza virus nucleoprotein. In agreement with recent studies, the optimal generation of functional memory CD8 T cells required CD4 help, although long-term maintenance of resting CD8 memory T cells